Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Darcy

Showing results (151-160 of 222) with videos related to

Pageof 23
Sort By:
Military Medicine|July 18, 2025
Superior Survival Outcomes of Epithelial Ovarian Cancer Patients in the Universal Access Military Healthcare System Compared With the National Surveillance, Epidemiology, and End Results ProgramKathleen M Darcy, Christopher M Tarney, Aimee B Park, et al.
Gynecologic Oncology|March 19, 2011
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignanciesLydia Usha, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|July 15, 2011
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group studyKian Behbakht, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|August 5, 2011
Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trialMeenakshi Singh, Kathleen M Darcy, William E Brady, et al.
Cancer Causes & Control : CCC|October 18, 2012
A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group studyRandy L Carter, Le Kang, Kathleen M Darcy, et al.
International Journal of Cancer|August 12, 2009
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United StatesShu-Yuan Liao, William H Rodgers, James Kauderer, et al.
Gynecologic Oncology|March 16, 2021
Racial disparities in high-risk uterine cancer histologic subtypes: A United States Cancer Statistics studyMary Kathryn Abel, Cheng-I Liao, Chloe Chan, et al.
Cancer|June 29, 2004
Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group studyRobert A Burger, Kathleen M Darcy, Philip J DiSaia, et al.
Gynecologic Oncology|November 17, 2009
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group studyShu-Yuan Liao, Kathleen M Darcy, Leslie M Randall, et al.
Journal of the National Cancer Institute|June 22, 2000
Rapid reporting and review of an increased incidence of a known adverse eventD J Sargent, R M Goldberg, M R Mahoney, et al.
Pageof 23

Showing results (151-160 of 222) with videos related to

Sort By:
Pageof 23
Military Medicine|July 18, 2025
Superior Survival Outcomes of Epithelial Ovarian Cancer Patients in the Universal Access Military Healthcare System Compared With the National Surveillance, Epidemiology, and End Results ProgramKathleen M Darcy, Christopher M Tarney, Aimee B Park, et al.
Gynecologic Oncology|March 19, 2011
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignanciesLydia Usha, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|July 15, 2011
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group studyKian Behbakht, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|August 5, 2011
Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trialMeenakshi Singh, Kathleen M Darcy, William E Brady, et al.
Cancer Causes & Control : CCC|October 18, 2012
A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group studyRandy L Carter, Le Kang, Kathleen M Darcy, et al.
International Journal of Cancer|August 12, 2009
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United StatesShu-Yuan Liao, William H Rodgers, James Kauderer, et al.
Gynecologic Oncology|March 16, 2021
Racial disparities in high-risk uterine cancer histologic subtypes: A United States Cancer Statistics studyMary Kathryn Abel, Cheng-I Liao, Chloe Chan, et al.
Cancer|June 29, 2004
Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group studyRobert A Burger, Kathleen M Darcy, Philip J DiSaia, et al.
Gynecologic Oncology|November 17, 2009
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group studyShu-Yuan Liao, Kathleen M Darcy, Leslie M Randall, et al.
Journal of the National Cancer Institute|June 22, 2000
Rapid reporting and review of an increased incidence of a known adverse eventD J Sargent, R M Goldberg, M R Mahoney, et al.
Pageof 23